drugset / Trial / NCT06925854

A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants

NCT06925854

Phase 1 Completed 12 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of rosuvastatin when administered alone and in combination with single oral dose of AZD4144.

Timeline

Start
2025-04-17
Primary completion
2025-06-12
Completion
2025-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4144 Unknown Oral
Subject Rosuvastatin Small molecule Oral

Indications

No indication recorded.